Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sention Inc.

www.sentionpharma.com

Latest From Sention Inc.

CoLucid Pharmaceuticals Inc.

CoLucid Pharmaceuticals starts out with an in-licensed migraine drug from Eli Lilly, one of a new class of molecules known as neurally acting anti-migraine agents. The phase II drug has demonstrated equal efficacy to triptans in the control of migraine symptoms without triptans' risk of cardiovascular side effects. CoLucid is also developing a wake-promotion drug using technology licensed from Sention.
BioPharmaceutical Strategy

Repurposing the Repurposing Business Model

Two recent examples of the difficulties of drug repurposing: Bionaut's ability to find new indications was not sufficient to get a foot in pharma's door without novelty to create barriers to entry to deter fast followers. Sention couldn't generate data fast enough on its L-amphetamine in improving cognitive impairment to counter amphetamine's bad image. (Its second program, even armed with pharma-vetted, baggage-less NCEs in-licensed from Merck, emerged too late to save the company.)
BioPharmaceutical Strategy

Exploiting Connections and Navigating Bumps Along the Brain-Gut Axis

The recent setback in SUI by Lilly's depression drug duloxetine may have implcations for a handful of biotech companies aiming to exploit their knowledge of the brain-gut axis to develop CNS drugs for IBS, OAB and other below-the-belt indications. Dynogen and Vela are two companies with promising products in the area.
BioPharmaceutical Strategy

Arachnova: The Patent Problem with Re-Indication Strategies

Dynogen and Arachnova both independently thought up a new indication for an unapproved but soon-to-genericize Mitsubishi anti-depressant. They both filed use patents, then both licensed the same preclinical data from Mitsubishi. Suddenly revealed to each other, they're now arguing over who owns the IP--a sobering message for the increasing number of companies pursuing re-indication strategies.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System > Cognition, Memory
  • Alias(es)
  • Nemogen Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sention Inc.
  • Senior Management
  • Kazumi Shiosaki, PhD, CSO
    David Manthus, PhD, VP, Reg. Affairs
  • Contact Info
  • Sention Inc.
    Phone: (401) 272-7177
    1 Richmond Square
    Providence, RI 02906
    USA
UsernamePublicRestriction

Register